Free tool
FAERS Monitor: Technelite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017771 or its brand name (Technelite, Technetium Tc-99m Sodium Pertechnetate Generator). Reports on generic versions are filed under their own applications.
Reports
16
Serious
4
25% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8
- dyspnoea2
- hypersensitivity2
- nausea2
- pruritus2
- vomiting2
- abdominal discomfort1
- accidental exposure to product1
- erythema1
- hot flush1
- hypotension1
- incorrect route of product administration1
- malaise1
- occupational exposure to product1
- occupational exposure to radiation1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| occupational exposure to radiation | 1 | 38702.5 | 5632.8 | 9,398 |
| occupational exposure to product | 1 | 204.5 | 30.7 | 50 |
| incorrect route of product administration | 1 | 76.7 | 11.5 | 18 |
| hot flush | 1 | 17.4 | 2.6 | 3 |
| hypersensitivity | 2 | 14.2 | 3.9 | 13 |
| accidental exposure to product | 1 | 12.8 | 1.9 | 2 |
| drug ineffectiveSignal | 8 | 8.0 | 4.9 | 45 |
| abdominal discomfort | 1 | 7.8 | 1.2 | 1 |
| pruritus | 2 | 6.8 | 1.9 | 5 |
| hypotension | 1 | 6.6 | 1.0 | 1 |
| erythema | 1 | 6.4 | 1.0 | 1 |
| vomiting | 2 | 5.6 | 1.5 | 4 |
| dyspnoea | 2 | 4.6 | 1.3 | 3 |
| nausea | 2 | 3.3 | 0.9 | 1 |
| malaise | 1 | 3.0 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.